CytomX Therapeutics, Inc. — Cash Flow Charts

8 quarters of history · ending 2025-12-31 · SEC EDGAR

Income Statement Cash Flow Balance Sheet Key Metrics

Source:10-K · 10-Q

Stock-Based Comp↓-21.5% -$405K

$1M

D&A↓-80.0% -$400K

$100K